Quick Answer
Inhibrx Biosciences, Inc. reported Stockholders Equity of $7.99 million for the year ending 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -94.0% in Stockholders Equity from 2024 to 2025.
- This data is from Inhibrx Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $15.13 million | Q2 2023: -$24.81 million | Q3 2023: $129.60 million | Q1 2024: $11.57 million | Q2 2024: $219.37 million | Q3 2024: $178.47 million | Q1 2025: $94.44 million | Q2 2025: $68.56 million | Q3 2025: $36.83 million.
- Over the full 4 years of available data (2022 to 2025), Inhibrx Biosciences, Inc.'s Stockholders Equity has declined by 86.2%.
- Historical annual values: Fiscal year 2025: $7.99 million | Fiscal year 2024: $133.58 million | Fiscal year 2023: $43.50 million | Fiscal year 2022: $58.06 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: